SEP 16·SEC EDGARLow
Greenwell Scott A. sold $874K of BTSG
Greenwell Scott A. (President, PharMerica) sold 15,099 shares of BrightSpring Health Services, Inc. (BTSG) at $57.91 ($0.87M total) on 2026-09-14 under a Rule 10b5-1 trading plan.
StockNASDAQ · US · USDHealthcare · Health Information Services
$BTSG
BrightSpring Health Services, Inc.
AlphAI earnings readsecond quarter 2026 · JUL 31BrightSpring Health Services, Inc. Reports Second Quarter 2026 Financial Results and Increases Full Year 2026 GuidanceVerdict: strongRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $BTSGvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $BTSG in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $874K 1 txs
Greenwell Scott A.1× · $874K
10b5-1 share of filings100%
Top stories · $BTSGMore →
SEP 5·yahoo.com
3 Lesser-Known Stocks Wall Street Is Pounding the Table on Now
APi Group (APG) reported Q2 2026 revenue of $2.3B, up 13.3% YoY, and raised full-year guidance. Analysts see 31% upside to $52.40. BrightSpring Health (BTSG) saw Q2 revenue rise 23% to $3.9B, lifted guidance, and has a 30% upside to $78.25.
AUG 21·tradingview.com
BrightSpring Stock Up Nearly 59% YTD: Can Its Growth Story Continue?
BrightSpring Health Services (BTSG) stock has risen 59% YTD, outperforming industry and S&P 500. Q2 2026 revenues grew 23% to $3.9B, adjusted EBITDA up 44%. Growth driven by Specialty Pharmacy and Provider Services, with AI/automation improving efficiency. Leverage reduced to 2.15x. 2026 EPS estimates raised to $1.78 (78% growth). Risks include execution challenges and reimbursement pressures.
BTSG sentiment & insider activity
Recent BTSG coverage spans earnings, financial news and insider activity.
In the last 30 days, BTSG insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($874K). The most active reporter was Greenwell Scott A., President, PharMerica, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving BTSG
The insider sale may signal reduced confidence and could exert slight downward pressure on the stock.
Robust earnings beat and higher guidance indicate strong upside.
Strong earnings beat and raised guidance suggest upside potential, especially given the 59% YTD rally.
The article frames a near-term earnings/margin risk from IRA reimbursement resets and pharmacy customer exits, partially offset by strong specialty and infusion growth plus improving EBITDA conversion.
Guidance lift and strong Specialty and Infusion growth are positives, but analyst questions highlight margin pressure in Pharmacy and ongoing regulatory/customer-exit headwinds.
AlphAI scores every news story that mentions BTSG with an AI model for sentiment and relevance, and aggregates insider trades from BrightSpring Health Services, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $BTSG
Score
Greenwell Scott A. sold $874K of BTSG
Greenwell Scott A. (President, PharMerica) sold 15,099 shares of BrightSpring Health Services, Inc. (BTSG) at $57.91 ($0.87M total) on 2026-09-14 under a Rule 10b5-1 trading plan.
1 min read
3 Lesser-Known Stocks Wall Street Is Pounding the Table on Now
APi Group (APG) reported Q2 2026 revenue of $2.3B, up 13.3% YoY, and raised full-year guidance. Analysts see 31% upside to $52.40. BrightSpring Health (BTSG) saw Q2 revenue rise 23% to $3.9B, lifted guidance, and has a 30% upside to $78.25.
3 min read
BrightSpring Stock Up Nearly 59% YTD: Can Its Growth Story Continue?
BrightSpring Health Services (BTSG) stock has risen 59% YTD, outperforming industry and S&P 500. Q2 2026 revenues grew 23% to $3.9B, adjusted EBITDA up 44%. Growth driven by Specialty Pharmacy and Provider Services, with AI/automation improving efficiency. Leverage reduced to 2.15x. 2026 EPS estimates raised to $1.78 (78% growth). Risks include execution challenges and reimbursement pressures.
3 min readHere's Why You Should Add BrightSpring Stock to Your Portfolio Now
Zacks says BrightSpring Health Services (BTSG) has growth momentum in Provider Services and Pharmacy Solutions, citing Q2 2026 Pharmacy Solutions revenue up 30% YoY to $2.9B and Provider Services up 30% to $466M. It also flags IRA reimbursement pressure, estimating about $50M impact in Q2 2026 and ~$200M full-year. BTSG shares are up 54.6% YTD; forward P/E 41.80.
7 min read
5 Revealing Analyst Questions From BrightSpring Health Services’s Q2 Earnings Call
BrightSpring Health Services (BTSG) reported Q2 revenue of $3.87B vs $3.66B expected and adjusted EPS of $0.45 vs $0.40, with adjusted EBITDA of $205.5M. The company raised full-year revenue guidance to $15.26B and EBITDA guidance to $832.5M. Management cited 30% Specialty and Infusion revenue growth and 31% script growth, while Home and Community Pharmacy faced customer exits and regulatory headwinds.
6 min readBTSG Raises 2026 Guidance as Specialty and Home Health Drive Growth
BrightSpring Health Services (BTSG) beat Q2 expectations with adjusted EPS of 45 cents (21.6% above consensus) and revenue of $3.87B (+23% YoY). It raised 2026 guidance to $15.10-$15.425B revenue and $820-$845M adjusted EBITDA. Specialty and infusion grew 30.1% and home health revenues rose 30.3%, while pharmacy fell 8% due to IRA impacts.
6 min readIs BTSG a Buy as Rapid Growth Collides With Its Premium Valuation?
BrightSpring Health Services (BTSG) reported Q2 revenues of $3.87B, up 23% YoY, and adjusted EPS of 45 cents, up 104.5%, beating Zacks estimates, and raised its full-year outlook. The article cites gross margin at 12.7% (+80 bps) and operating margin up 180 bps. It notes forward P/E of 30.7x and expects IRA reimbursement impacts of about $45M per quarter in 2026.
6 min readBTSG Drops 18.1% in One Week as Growth Meets Fresh Valuation Risks
BrightSpring Health Services (BTSG) shares fell 18.1% over the past week after better-than-expected Q2 results and raised guidance. Q2 revenue rose 23% to $3.87B and adjusted EPS rose 104.5% to 45 cents. 2026 guidance was raised to $15.1-$15.425B revenue and $820-$845M adjusted EBITDA, but investors cited valuation risk and policy-driven reimbursement pressure.
6 min readDoes BrightSpring (BTSG) Upgraded 2026 Revenue Outlook Reinforce or Stretch Its Long-Term Growth Narrative?
Simply Wall St reports BrightSpring Health Services (BTSG) posted Q2 2026 revenue of $3.87B and net income of $84.29M, with higher EPS year over year. The company raised full-year 2026 revenue guidance to $15.10B-$15.43B. The piece discusses implications for its long-term growth and margin outlook.
7 min readWhy BrightSpring Health Services (BTSG) Shares Are Trading Lower Today
BrightSpring Health Services (NASDAQ: BTSG) shares fell 17.5% after the company reported Q2 revenue up 23% to $3.87B and non-GAAP EPS of $0.45, alongside higher full-year guidance. Despite the beat and raise, investors reacted negatively, citing valuation and stagnant profit margins.
3 min read